Republic Services Inc. Common Stock vs Sana Biotechnology Inc — how do they compare? Republic Services Inc. Common Stock trades at $225.58 (market cap $67.34B), while Sana Biotechnology Inc trades at $2.34 (market cap $719.96M). The key difference: Republic Services Inc. Common Stock is far larger — about 93.5× Sana Biotechnology Inc's market cap, and Republic Services Inc. Common Stock pays a 1.22% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| RSG | SANA | |
|---|---|---|
Market Cap | $67.34B | $719.96M |
Volume | 955,255 | 4,901,517 |
Sector | Industrials | Health |
52-Week High | $232.27 | $5.92 |
52-Week Low | $197.73 | $2.33 |
Enterprise Value | $81.53B | $633.21M |
Dividend Yield | 1.22% | — |
Typical Hold Time | — | 24 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SANA Biotechnology trades at $2.41, down 8.02% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company shows no revenue with substantial losses (-$244.17M net income in 2025) and negative cash flow, though analyst consensus remains strongly positive with 82% buy ratings. Recent investor conference presentations indicate active business development efforts.
The stock presents high-risk speculative potential with strong Wall Street support but faces fundamental challenges including no revenue generation and significant cash burn. Investment opportunity hinges on successful clinical developments, while risks include continued operational losses and potential dilution from financing activities.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Republic Services Inc. is a waste management company that provides non-hazardous solid waste collection, transfer, disposal, and recycling services across North America.
Read more on RSG →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →